Antihypertensive Drugs Market by Drug Class, Form, Indication, Distribution Channel, End-User - Global Forecast 2025-2030- Product Image

Sale

Antihypertensive Drugs Market by Drug Class, Form, Indication, Distribution Channel, End-User - Global Forecast 2025-2030

Report
195 Pages
October 2024
Region: Global
360iResearch™
ID: 5715523

UP TO €689EUR$697USD£573GBP OFF until Dec 31^st 2024

The Antihypertensive Drugs Market grew from USD 24.70 billion in 2023 to USD 25.76 billion in 2024. It is expected to continue growing at a CAGR of 4.66%, reaching USD 33.99 billion by 2030.

Antihypertensive drugs are medications used for managing hypertension, a chronic medical condition characterized by persistently elevated blood pressure. The necessity for these drugs is primarily driven by the global epidemic of hypertension, which is a leading risk factor for cardiovascular diseases, stroke, and kidney failure. Their application spans from first-line monotherapy to combination therapy, often tailored to the patient's specific health profile and the underlying causes of hypertension. End-use sectors include hospitals, clinics, and home care settings, with a growing market for personalized medicine driven by advances in genomic understanding. Key growth factors in this market include the rise in geriatric population, increasing prevalence of hypertension due to lifestyle changes, and significant R&D investments by pharmaceutical companies. Additionally, innovations in drug delivery technologies and the development of fixed-dose combinations that increase patient compliance present fresh opportunities. Companies could leverage these by focusing on precision medicine and expanding their portfolios to include natural and alternative remedies. Nevertheless, the market faces challenges related to high development costs, stringent regulatory policies, and potential side effects associated with long-term drug use, which may deter some patients from adhering to treatment regimens. Expanding research into novel antihypertensive agents targeting different pathways and collaborating with tech companies for digital health solutions can foster business growth and innovation. Furthermore, geographical markets with historically low healthcare access present untapped opportunities. The nature of the antihypertensive drugs market is highly competitive, with many prominent players, necessitating continuous innovation and strategic partnerships to maintain a competitive edge. It is also crucial to navigate the patent landscape smartly to prevent generic erosion and ensure sustainable growth across diverse market segments.

Understanding Market Dynamics in the Antihypertensive Drugs Market

The Antihypertensive Drugs Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.

Market Drivers
- Surging prevalence of hypertension, along with the growing geriatric population
- Increase in healthcare expenditure worldwide
- Growing consumer awareness of early diagnosis and treatment
Market Restraints
- Stringent approval process and huge costs involved in drug development
Market Opportunities
- Introduction of a new class of antihypertensive drugs
- Surge in approvals of novel drugs from regulatory bodies
Market Challenges
- Concern regarding adverse health outcomes of antihypertensive drugs

Exploring Porter’s Five Forces for the Antihypertensive Drugs Market

Porter’s Five Forces framework further strengthens the insights of the Antihypertensive Drugs Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Antihypertensive Drugs Market

External macro-environmental factors deeply influence the performance of the Antihypertensive Drugs Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Antihypertensive Drugs Market

The Antihypertensive Drugs Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Antihypertensive Drugs Market

The Antihypertensive Drugs Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Antihypertensive Drugs Market

The Antihypertensive Drugs Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antihypertensive Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alembic Pharmaceuticals Limited, Alkem Laboratories, Apikos Pharma, AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Centurion Remedies Private Limited, Daiichi Sankyo Co., Ltd., Dr. Reddy's Laboratories, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., Glenmark Pharmaceuticals Ltd., Johnson & Johnson Services, Inc., Lupin Ltd., Merck & Co., Inc., Novartis AG, Sanofi S.A., Saphnix Lifesciences, Schwitz Biotech, Sun Pharmaceutical Industries Limited, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., United Therapeutics Corporation, and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Antihypertensive Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug Class
- Alpha-Blockers
- Angiotensin Converting Enzyme Inhibitors
- Angiotensin Receptor Blockers
- Beta-Blockers
- Calcium Channel Blockers
- Diuretics
- Renin Inhibitors
- Vasodilators
Form
- Intravenous Injections
- Oral Tablets/Capsules
- Transdermal Patches
Indication
- Primary Hypertension
- Secondary Hypertension
Distribution Channel
- Offline
- Online
End-User
- Home Care Facilities
- Hospitals & Clinics

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

What is the current size of the market, and how is it expected to grow?
Which products, segments, and regions present the most attractive investment opportunities?
What are the prevailing technology trends and regulatory factors influencing the market?
How do top vendors rank regarding market share and competitive positioning?
What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
4. Market Overview

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Surging prevalence of hypertension, along with the growing geriatric population
5.1.1.2. Increase in healthcare expenditure worldwide
5.1.1.3. Growing consumer awareness of early diagnosis and treatment
5.1.2. Restraints
5.1.2.1. Stringent approval process and huge costs involved in drug development
5.1.3. Opportunities
5.1.3.1. Introduction of a new class of antihypertensive drugs
5.1.3.2. Surge in approvals of novel drugs from regulatory bodies
5.1.4. Challenges
5.1.4.1. Concern regarding adverse health outcomes of antihypertensive drugs
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental

6. Antihypertensive Drugs Market, by Drug Class

6.1. Introduction
6.2. Alpha-Blockers
6.3. Angiotensin Converting Enzyme Inhibitors
6.4. Angiotensin Receptor Blockers
6.5. Beta-Blockers
6.6. Calcium Channel Blockers
6.7. Diuretics
6.8. Renin Inhibitors
6.9. Vasodilators

7. Antihypertensive Drugs Market, by Form

7.1. Introduction
7.2. Intravenous Injections
7.3. Oral Tablets/Capsules
7.4. Transdermal Patches

8. Antihypertensive Drugs Market, by Indication

8.1. Introduction
8.2. Primary Hypertension
8.3. Secondary Hypertension

9. Antihypertensive Drugs Market, by Distribution Channel

9.1. Introduction
9.2. Offline
9.3. Online

10. Antihypertensive Drugs Market, by End-User

10.1. Introduction
10.2. Home Care Facilities
10.3. Hospitals & Clinics

11. Americas Antihypertensive Drugs Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Antihypertensive Drugs Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Antihypertensive Drugs Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.4. Strategy Analysis & Recommendation

List of Figures

FIGURE 1. ANTIHYPERTENSIVE DRUGS MARKET RESEARCH PROCESS
FIGURE 2. ANTIHYPERTENSIVE DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 7. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2023 VS 2030 (%)
FIGURE 9. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 11. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 13. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 15. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 19. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. ASIA-PACIFIC ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. ASIA-PACIFIC ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. ANTIHYPERTENSIVE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 25. ANTIHYPERTENSIVE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

List of Tables

TABLE 1. ANTIHYPERTENSIVE DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. ANTIHYPERTENSIVE DRUGS MARKET DYNAMICS
TABLE 7. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ALPHA-BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ANGIOTENSIN CONVERTING ENZYME INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY BETA-BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DIURETICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY RENIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY VASODILATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INTRAVENOUS INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ORAL TABLETS/CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY TRANSDERMAL PATCHES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY PRIMARY HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY SECONDARY HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOME CARE FACILITIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 35. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 36. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 37. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 38. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 39. ARGENTINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 40. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 41. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 43. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 44. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 45. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 46. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 47. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 48. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 49. CANADA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 50. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 51. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 52. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 53. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 54. MEXICO ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 61. ASIA-PACIFIC ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 62. ASIA-PACIFIC ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 63. ASIA-PACIFIC ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 64. ASIA-PACIFIC ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. ASIA-PACIFIC ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 66. ASIA-PACIFIC ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 67. AUSTRALIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 68. AUSTRALIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 69. AUSTRALIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 70. AUSTRALIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 71. AUSTRALIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 72. CHINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 73. CHINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 74. CHINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 75. CHINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. CHINA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 77. INDIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 78. INDIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 79. INDIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 80. INDIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. INDIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 82. INDONESIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 83. INDONESIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 84. INDONESIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 85. INDONESIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 86. INDONESIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 87. JAPAN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 88. JAPAN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 89. JAPAN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 90. JAPAN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 91. JAPAN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 92. MALAYSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 93. MALAYSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 94. MALAYSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 95. MALAYSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. MALAYSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 97. PHILIPPINES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 98. PHILIPPINES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 99. PHILIPPINES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 100. PHILIPPINES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. PHILIPPINES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 102. SINGAPORE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 103. SINGAPORE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 104. SINGAPORE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 105. SINGAPORE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. SINGAPORE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 107. SOUTH KOREA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 108. SOUTH KOREA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 109. SOUTH KOREA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 110. SOUTH KOREA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 111. SOUTH KOREA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 112. TAIWAN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 113. TAIWAN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 114. TAIWAN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 115. TAIWAN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 116. TAIWAN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 117. THAILAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 118. THAILAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 119. THAILAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 120. THAILAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 121. THAILAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 122. VIETNAM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 123. VIETNAM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 124. VIETNAM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 125. VIETNAM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. VIETNAM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 133. DENMARK ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 134. DENMARK ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 135. DENMARK ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 136. DENMARK ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 137. DENMARK ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 138. EGYPT ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 139. EGYPT ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 140. EGYPT ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 141. EGYPT ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. EGYPT ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 143. FINLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 144. FINLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 145. FINLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 146. FINLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 147. FINLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 148. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 149. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 150. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 151. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 152. FRANCE ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 153. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 154. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 155. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 156. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 157. GERMANY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 158. ISRAEL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 159. ISRAEL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 160. ISRAEL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 161. ISRAEL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 162. ISRAEL ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 163. ITALY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 164. ITALY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 165. ITALY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 166. ITALY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 167. ITALY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 168. NETHERLANDS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 169. NETHERLANDS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 170. NETHERLANDS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 171. NETHERLANDS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 172. NETHERLANDS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 173. NIGERIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 174. NIGERIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 175. NIGERIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 176. NIGERIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 177. NIGERIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 178. NORWAY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 179. NORWAY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 180. NORWAY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 181. NORWAY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. NORWAY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 183. POLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 184. POLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 185. POLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 186. POLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 187. POLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 188. QATAR ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 189. QATAR ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 190. QATAR ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 191. QATAR ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 192. QATAR ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 200. SAUDI ARABIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 201. SAUDI ARABIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 202. SAUDI ARABIA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 208. SPAIN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 209. SPAIN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 210. SPAIN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 211. SPAIN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 212. SPAIN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 213. SWEDEN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 214. SWEDEN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 215. SWEDEN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 216. SWEDEN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 217. SWEDEN ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 218. SWITZERLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 219. SWITZERLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 220. SWITZERLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 221. SWITZERLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 222. SWITZERLAND ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 223. TURKEY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 224. TURKEY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 225. TURKEY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 226. TURKEY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 227. TURKEY ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 234. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 236. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 238. ANTIHYPERTENSIVE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 239. ANTIHYPERTENSIVE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Antihypertensive Drugs Market, which are profiled in this report, include:

Abbott Laboratories
Alembic Pharmaceuticals Limited
Alkem Laboratories
Apikos Pharma
AstraZeneca PLC
Bayer AG
Boehringer Ingelheim International GmbH
Centurion Remedies Private Limited
Daiichi Sankyo Co., Ltd.
Dr. Reddy's Laboratories
F. Hoffmann-La Roche AG
Gilead Sciences, Inc.
Glenmark Pharmaceuticals Ltd.
Johnson & Johnson Services, Inc.
Lupin Ltd.
Merck & Co., Inc.
Novartis AG
Sanofi S.A.
Saphnix Lifesciences
Schwitz Biotech
Sun Pharmaceutical Industries Limited
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.
United Therapeutics Corporation
Zydus Lifesciences Limited

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	195
Published	October 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 25.76 Billion
Forecasted Market Value ( USD ) by 2030	$ 33.99 Billion
Compound Annual Growth Rate	4.6%
Regions Covered	Global
No. of Companies Mentioned	25

License	Format	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access		This is a single user license, allowing one user access to the product.	€3503EUR$3,545USD£2,915GBP €3892EUR$3,939USD£3,239GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€6197EUR$6,272USD£5,158GBP €6886EUR$6,969USD£5,731GBP

Understanding Market Dynamics in the Antihypertensive Drugs Market

Exploring Porter’s Five Forces for the Antihypertensive Drugs Market

Applying PESTLE Analysis to the Antihypertensive Drugs Market

Analyzing Market Share in the Antihypertensive Drugs Market

Evaluating Vendor Success with the FPNV Positioning Matrix in the Antihypertensive Drugs Market

Strategic Recommendations for Success in the Antihypertensive Drugs Market

Key Company Profiles

Market Segmentation & Coverage

The report provides a detailed overview of the market, exploring several key areas:

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Antihypertensive Drugs Market Report by Therapeutic Class, Type, Distribution Channel, and Region 2024-2032

Cardiovascular Therapeutics Market by Drug Class, Indication, Patient Demographics, End-User, Route of Administration, Distribution Channel - Global Forecast 2025-2030

Critical Limb Ischemia Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

North America ACE Inhibitors Market, By Country, Competition, Forecast & Opportunities, 2019-2029F

Cardiovascular Drugs - Global Strategic Business Report

About the Antihypertensive Market